Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Shufeng LiuTianyi Wang

Abstract

Hepatitis C virus (HCV) entry is a multiple-step process involving a number of host factors and hence represents a promising target for new antiviral drug development. In search of novel inhibitors of HCV infection, we found that a human apolipoprotein E (apoE) peptide, hEP, containing both a receptor binding fragment and a lipid binding fragment of apoE specifically blocked the entry of cell culture grown HCV (HCVcc) at submicromolar concentrations. hEP caused little cytotoxicity in vitro and remained active even if left 24 hours in cell culture. Interestingly, hEP inhibited neither human immunodeficiency virus (HIV)-HCV pseudotypes (HCVpp) nor HIV and Dengue virus (DENV) infection. Further characterization mapped the anti-HCV activity to a 32-residue region that harbors the receptor binding domain of apoE, but this fragment must contain a cysteine residue at the N-terminus to mediate dimer formation. The anti-HCV activity of the peptide appears to be dependent on both its length and sequence and correlates with its ability to bind lipids. Finally, we demonstrated that the apoE-derived peptides directly blocked the binding of both HCVcc and patient serum-derived virus to hepatoma cells as well as primary human hepatocytes. apo...Continue Reading

References

Oct 30, 1998·Science·P PileriS Abrignani
Sep 26, 2003·The Journal of Biological Chemistry·John R LynchDaniel T Laskowitz
Aug 7, 2004·Traffic·Clare Jolly, Quentin J Sattentau
Feb 26, 2005·Seminars in Liver Disease·Patrice AndréVincent Lotteau
Jun 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jin ZhongFrancis V Chisari
Jun 11, 2005·Science·Brett D LindenbachCharles M Rice
Jul 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ralf Bartenschlager, Thomas Pietschmann
Jan 3, 2006·The Journal of Infectious Diseases·Curtis B DobsonKeith A Crutcher
May 16, 2006·Journal of Virology·George KoutsoudakisRalf Bartenschlager
Jul 6, 2006·Trends in Biochemical Sciences·Danny M HattersKarl H Weisgraber
Sep 30, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Simone SusserChristoph Sarrazin
Oct 28, 2009·Biology of the Cell·Costin-Ioan Popescu, Jean Dubuisson
Dec 17, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Wagane J A BengaCatherine Schuster
Sep 9, 2010·Virology·Shufeng LiuTianyi Wang
Sep 10, 2010·Journal of Virology·Takayuki HishikiKunitada Shimotohno
Nov 9, 2010·The Journal of Biological Chemistry·Andreas MerzRalf Bartenschlager
Jun 28, 2011·Gastroenterology·Gang LongRalf Bartenschlager

❮ Previous
Next ❯

Citations

Nov 1, 2012·Seminars in Immunopathology·M F BassendineR D G Neely
Jul 16, 2014·Critical Reviews in Biotechnology·Jeong-Hun KangMasaharu Murata
Aug 5, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zhilei Chen, Charles M Rice
Jul 15, 2015·Scientific Reports·André F FaustinoNuno C Santos
Sep 13, 2016·ACS Infectious Diseases·Che C ColpittsThomas F Baumert
Jan 6, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Philippe SultanikUNKNOWN ANRS CO20-CUPIC
Aug 25, 2015·Biomaterials·Jinjin ZhangNatalia A Osna
Aug 14, 2012·Biochimie·Julie Blaising, Eve-Isabelle Pécheur
May 12, 2015·Future Virology·Sarah C Ogden, Hengli Tang
Feb 24, 2016·Scientific Reports·Jun-Jun ChengJian-Dong Jiang
May 26, 2017·Journal of Virology·Zhihua LiShaozhong Dong
Aug 9, 2019·PLoS Pathogens·Luhua Qiao, Guangxiang George Luo
Jun 4, 2019·Current Opinion in Lipidology·Eftaxia-Konstantina ValantiDespina Sanoudou
Apr 28, 2020·Current Topics in Medicinal Chemistry·Rosa GaglioneAngela Arciello
May 8, 2019·Biological & Pharmaceutical Bulletin·Yoshitaka ShirasagoMasayoshi Fukasawa
Nov 5, 2016·Gut·Philippe RoingeardJean-Christophe Meunier
Jun 20, 2017·Expert Review of Proteomics·Emilie CrouchetCatherine Schuster
Jul 19, 2017·Insect Molecular Biology·Z L WagarM J Conway
Mar 22, 2020·International Journal of Molecular Sciences·Che C ColpittsMirjam B Zeisel
Apr 28, 2019·International Journal of Molecular Sciences·Yue Gong, Wei Cun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.